What is 4baseCare?
Headquartered in Karnataka, India, 4baseCare specializes in the development of affordable and accessible precision oncology solutions. The company integrates next-generation sequencing, advanced genomics, and digital health technology to provide actionable insights that enable clinicians to tailor therapeutic interventions to the unique genetic profile of each patient. By bridging the gap between complex genomic data and bedside clinical decision-making, 4baseCare is effectively positioning itself as a critical infrastructure provider in the modern oncology ecosystem. Its market position is defined by a commitment to reducing the cost of high-end diagnostics, thereby expanding access to personalized medicine in emerging markets.
How much funding has 4baseCare raised?
4baseCare has raised a total of $22M across 4 funding rounds:
Other Financing Round
$2M
Other Financing Round
$6M
Unspecified
$1M
Series B
$13M
Other Financing Round (2021): $2M with participation from Season Two Ventures, Mount Judi Ventures LLP, growX ventures, and First In Ventures
Other Financing Round (2024): $6M led by Yali Capital Partners
Unspecified (2024): $1M supported by Infosys
Series B (2026): $13M featuring Growx, Kk
Key Investors in 4baseCare
Infosys
Infosys is a global leader in next-generation digital services and consulting, providing expertise in AI, automation, and data analytics to drive enterprise-level digital transformation.
Yali Capital Partners
Yali Capital Partners is an investment banking firm focused on identifying and supporting high-growth potential companies through strategic capital allocation.
growX ventures
growX ventures is an early-stage venture capital firm that partners with technology-driven startups to provide the necessary capital and mentorship for rapid market expansion.
What's next for 4baseCare?
With the infusion of $13M, 4baseCare is well-positioned to enter a new phase of operational scaling and technological refinement. The strategic roadmap likely involves the expansion of its genomic database, the enhancement of its digital health software suite, and the pursuit of broader clinical partnerships to validate its diagnostic efficacy. As the company transitions into a more mature lifecycle stage, the focus will shift toward commercializing its precision oncology tools at scale and navigating the regulatory landscapes of international markets. Investors are expected to monitor the company's ability to maintain its competitive edge in data-driven diagnostics while continuing to drive down the cost of care, a critical factor for long-term sustainability in the global health-tech sector.
See full 4baseCare company page
